네오항원 시장 규모, 점유율, 성장 분석 : 치료법별, 암 유형별, 개발 단계별, 최종사용자별, 기술별, 지역별 - 업계 예측(2026-2033년)

Global Neoantigen Market size was valued at USD 1.87 Billion in 2024 and is poised to grow from USD 2.21 Billion in 2025 to USD 8.56 Billion by 2033, growing at a CAGR of 18.4% during the forecast period (2026-2033).

The global neoantigen market focuses on the discovery, manufacturing, and clinical implementation of cancer vaccines targeting tumor-specific mutated peptides, highlighting their ability to elicit strong immune responses without harming healthy tissue. This market has evolved significantly, driven by advances in genomic sequencing, bioinformatics, and peptide synthesis, transforming it from a niche research area into a dynamic commercial sector. Regulatory support is vital, as clear pathways for approval enhance investor confidence and drive venture capital toward innovative firms utilizing AI-driven epitope selection. This technology expedites the design and manufacturing processes, shortening development timelines and increasing preclinical validation speed. As hospitals integrate neoantigen trials into oncology treatment protocols, investments will rise, stimulating research and expanding reimbursement opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neoantigen market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neoantigen Market Segments Analysis

Global neoantigen market is segmented by therapy type, cancer type, development stage, end user, technology and region. Based on therapy type, the market is segmented into Personalized Neoantigen Vaccines, Shared Neoantigen Vaccines, Neoantigen-Based T Cell Therapies and Combination Therapies. Based on cancer type, the market is segmented into Melanoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer and Others. Based on development stage, the market is segmented into Discovery, Preclinical, Clinical and Commercial. Based on end user, the market is segmented into Biotechnology Companies, Pharmaceutical Companies, Academic & Research Institutes and Cancer Centers. Based on technology, the market is segmented into DNA Sequencing, Bioinformatics Platforms, AI-Based Neoantigen Prediction and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neoantigen Market

A key market driver for the global neoantigen market is the increasing prevalence of cancers worldwide and the subsequent demand for personalized immunotherapies. As conventional cancer treatments often exhibit limited effectiveness and can cause significant side effects, there is a growing emphasis on targeted therapies that leverage the unique mutations present in individual tumors. Neoantigens, which arise from these mutations, represent a compelling approach for tailoring immune responses to attack cancer cells specifically. This heightened focus on personalized medicine, combined with advancements in genomic sequencing technologies, is driving research and development in neoantigen-based therapies, propelling market growth.

Restraints in the Global Neoantigen Market

A significant restraint in the global neoantigen market is the complex and lengthy process of neoantigen discovery and validation. Developing personalized neoantigen-based therapies demands extensive research and sophisticated technologies, which can be cost-prohibitive and time-consuming. Additionally, challenges related to regulatory approval and the need for rigorous clinical trials can further hinder market growth. The requirement for advanced bioinformatics tools and the variability in patient tumor profiles add layers of complexity, making it difficult for companies to scale production effectively. These factors may deter investment and slow down the overall adoption of neoantigen therapies in clinical settings.

Market Trends of the Global Neoantigen Market

The Global Neoantigen market is experiencing a significant shift towards personalized immunogenic platforms, driven by advancements in high-throughput sequencing and AI-based epitope prediction technologies. These innovations are facilitating the rapid identification of patient-specific neoantigens, which are extending therapeutic applications beyond traditional melanoma treatments to encompass various solid tumors, including lung, colorectal, and ovarian cancers. This trend is prompting a collaborative ecosystem among biotech companies, diagnostic providers, and academic institutions, fostering the development of integrated pipelines that prioritize the delivery of tailored immunotherapies. This strategic focus aims to streamline development timelines while ensuring compliance with regulatory standards and maintaining patient safety on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Neoantigen Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Personalized Neoantigen Vaccines
• Shared Neoantigen Vaccines
• Neoantigen-Based T Cell Therapies
• Combination Therapies

Global Neoantigen Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Melanoma
• Non-Small Cell Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Others

Global Neoantigen Market Size by Development Stage & CAGR (2026-2033)

• Market Overview
• Discovery
• Preclinical
• Clinical
• Commercial

Global Neoantigen Market Size by End User & CAGR (2026-2033)

• Market Overview
• Biotechnology Companies
• Pharmaceutical Companies
• Academic & Research Institutes
• Cancer Centers

Global Neoantigen Market Size by Technology & CAGR (2026-2033)

• Market Overview
• DNA Sequencing
• Bioinformatics Platforms
• AI-Based Neoantigen Prediction
• Others

Global Neoantigen Market Size & CAGR (2026-2033)

• North America (Therapy Type, Cancer Type, Development Stage, End User, Technology)
  • US
  • Canada
• Europe (Therapy Type, Cancer Type, Development Stage, End User, Technology)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Cancer Type, Development Stage, End User, Technology)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Cancer Type, Development Stage, End User, Technology)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Cancer Type, Development Stage, End User, Technology)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• BioNTech SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gritstone bio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nouscom AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evaxion Biotech A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Geneos Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CureVac N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NEC Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ultimovacs ASA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Personalis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tempus AI, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Nanopore Technologies plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Encode Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anixa Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations